MX2020007375A - Terapias de combinacion para el tratamiento de carcinoma hepatocelular. - Google Patents

Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Info

Publication number
MX2020007375A
MX2020007375A MX2020007375A MX2020007375A MX2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A
Authority
MX
Mexico
Prior art keywords
treatment
hepatocellular carcinoma
combination therapies
combination
lenvatinib
Prior art date
Application number
MX2020007375A
Other languages
English (en)
Inventor
Peter Smith
Anand Selvaraj
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2020007375A publication Critical patent/MX2020007375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona en la presente una terapia de combinación útil para el tratamiento de carcinoma hepatocelular. La combinación comprende un inhibidor de FGFR4 y lenvatinib.
MX2020007375A 2018-01-10 2019-01-09 Terapias de combinacion para el tratamiento de carcinoma hepatocelular. MX2020007375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10
PCT/US2019/012886 WO2019139977A1 (en) 2018-01-10 2019-01-09 Combination therapies for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2020007375A true MX2020007375A (es) 2020-11-09

Family

ID=65411938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007375A MX2020007375A (es) 2018-01-10 2019-01-09 Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Country Status (13)

Country Link
US (1) US11833119B2 (es)
EP (2) EP3737377B1 (es)
JP (2) JP7352569B2 (es)
KR (2) KR102811519B1 (es)
CN (1) CN111787922A (es)
AU (1) AU2019206480A1 (es)
BR (1) BR112020014112A2 (es)
CA (1) CA3088292A1 (es)
IL (1) IL275981A (es)
MA (1) MA51570A (es)
MX (1) MX2020007375A (es)
SG (1) SG11202006617RA (es)
WO (1) WO2019139977A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021230886A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
CN117479958A (zh) * 2022-05-30 2024-01-30 石药集团中奇制药技术（石家庄）有限公司 用于治疗癌症的药物组合和药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
KR100839554B1 (ko) 2003-12-25 2008-06-20 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의결정 및 이들의 제조 방법
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
KR20140117457A (ko) * 2012-01-31 2014-10-07 노파르티스 아게 Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
SMT201800379T1 (it) 2013-10-18 2018-09-13 Eisai R&D Man Co Ltd Inibitori di fgfr4 della pirimidina
AU2015238305B2 (en) * 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US20160089365A1 (en) 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
EP3454898B1 (en) * 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation

Also Published As

Publication number Publication date
CA3088292A1 (en) 2019-07-18
BR112020014112A2 (pt) 2020-12-01
JP2021512140A (ja) 2021-05-13
US11833119B2 (en) 2023-12-05
IL275981A (en) 2020-08-31
US20200360371A1 (en) 2020-11-19
EP4667005A3 (en) 2026-02-18
JP7665700B2 (ja) 2025-04-21
KR20250073570A (ko) 2025-05-27
KR20200121302A (ko) 2020-10-23
RU2020126673A3 (es) 2022-04-19
AU2019206480A1 (en) 2020-08-27
EP4667005A2 (en) 2025-12-24
JP7352569B2 (ja) 2023-09-28
EP3737377B1 (en) 2025-10-08
MA51570A (fr) 2020-11-18
JP2023175825A (ja) 2023-12-12
KR102811519B1 (ko) 2025-05-22
SG11202006617RA (en) 2020-08-28
EP3737377A1 (en) 2020-11-18
CN111787922A (zh) 2020-10-16
RU2020126673A (ru) 2022-02-10
WO2019139977A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
JOP20190272A1 (ar) مثبطات kras g12c وطرق لاستخدامها
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CY1122283T1 (el) Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια
EP4302835A3 (en) Methods of treating ovarian cancer
EA201790398A1 (ru) Способы лечения заболевания печени
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX387283B (es) Tratamiento del cancer con tg02.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
EA201692436A1 (ru) Медицинское применение
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
MX2020013728A (es) Combinacion de inmunoterapias con inhibidores de mdm2.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
BR112019003722A2 (pt) terapias de combinação para o tratamento de carcinoma hepatocelular
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.
WO2019170283A8 (en) Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
EP4667005A3 (en) Combination therapies for the treatment of hepatocellular carcinoma
CL2020000586A1 (es) Moduladores de la expresión de enac.
MX2020011912A (es) Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).